LinkedIn Profile

Access Topica Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Sector Industry
private:topicapharmaceuticals 828526 Mar 9th, 2018 12:00AM Topica Pharmaceuticals 113 2.00 Open Pharmaceuticals Mar 8th, 2018 11:12PM Mar 8th, 2018 11:12PM Open Oil & Gas Pharmaceuticals & Biotechnology
private:topicapharmaceuticals 828526 Feb 17th, 2018 12:00AM Topica Pharmaceuticals 113 2.00 Open Pharmaceuticals Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization. Oil & Gas Pharmaceuticals & Biotechnology
private:topicapharmaceuticals 828526 Feb 16th, 2018 12:00AM Topica Pharmaceuticals 113 2.00 Open Pharmaceuticals Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization. Oil & Gas Pharmaceuticals & Biotechnology
private:topicapharmaceuticals 828526 Feb 15th, 2018 12:00AM Topica Pharmaceuticals 113 2.00 Open Pharmaceuticals Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization. Oil & Gas Pharmaceuticals & Biotechnology
private:topicapharmaceuticals 828526 Feb 14th, 2018 12:00AM Topica Pharmaceuticals 113 2.00 Open Pharmaceuticals Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization. Oil & Gas Pharmaceuticals & Biotechnology
private:topicapharmaceuticals 828526 Feb 13th, 2018 12:00AM Topica Pharmaceuticals 113 2.00 Open Pharmaceuticals Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization. Oil & Gas Pharmaceuticals & Biotechnology
private:topicapharmaceuticals 828526 Feb 12th, 2018 12:00AM Topica Pharmaceuticals 113 2.00 Open Pharmaceuticals Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization. Oil & Gas Pharmaceuticals & Biotechnology
private:topicapharmaceuticals 828526 Feb 11th, 2018 12:00AM Topica Pharmaceuticals 113 2.00 Open Pharmaceuticals Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization. Oil & Gas Pharmaceuticals & Biotechnology
private:topicapharmaceuticals 828526 Feb 10th, 2018 12:00AM Topica Pharmaceuticals 113 2.00 Open Pharmaceuticals Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization. Oil & Gas Pharmaceuticals & Biotechnology
private:topicapharmaceuticals 828526 Feb 9th, 2018 12:00AM Topica Pharmaceuticals 113 2.00 Open Pharmaceuticals Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization. Oil & Gas Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.